Nephrotic livers secrete normal VLDL that acquire structural and functional defects following interaction with HDL  by Shearer, Gregory C. et al.
Kidney International, Vol. 65 (2004), pp. 228–237
Nephrotic livers secrete normal VLDL that acquire structural
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Nephrotic livers secrete normal VLDL that acquire structural
and functional defects following interaction with HDL.
Background. Binding of very low-density lipoprotein
(VLDL) isolated from serum of nephrotic rats VLDL to en-
dothelial cells is defective. This defect is conferred on normal
VLDL by prior incubation with high-density lipoprotein (HDL)
from nephrotic, but not control rats. It is not known whether the
defect is present in nascent VLDL (nVLDL) or is acquired after
secretion. We test the hypothesis that VLDL is normal at the
time of secretion from the liver and the defect in binding to en-
dothelium is conferred following secretion through interaction
with HDL.
Methods. nVLDL was synthesized by and collected from
isolated perfused livers from either control or nephrotic rats.
nVLDL was labeled with 3H-oleate to measure binding and
35S methionine to evaluate apolipoprotein exchange and com-
position. To test whether HDL conferred a binding defect,
nVLDL was incubated with HDL obtained either from con-
trol or nephrotic rats prior to measurement of binding. To
distinguish the effects of proteinuria from reduced albumin con-
centration we additionally incubated nVLDL with HDL ob-
tained from rats with hereditary analbuminemia. Both HDL
and VLDL were reisolated by centrifugation prior to sub-
sequent binding and lipolysis determination. Exchange of
35S-labeled apolipoprotein E (apoE) among the subsequent
VLDL and HDL fractions was determined. To determine the
effect of HDL on lipolysis, HDL-treated VLDL was exposed to
lipoprotein lipase–coated 96-well plates and 3H-oleate release
measured. To establish whether differences in apoE content
could explain the differences in binding and lipolysis, apoE was
restored to nephrotic VLDL and lipolysis and binding were
subsequently measured.
Results. Binding of nephrotic nVLDL was greater than con-
trol nVLDL (0.58 ± 0.13 vs. 0.75 ± 0.07 ng protein bound/mg
cell protein) (P = 0.04, N = 6). Lipolysis was similarly elevated
(0.091 ± 0.010 vs 0.064 ± 0.002 nmol NEFA released/well/hour)
(P < 0.05). Prior incubation with nephrotic HDL reduced bind-
ing of nVLDL obtained from either nephrotic or control liv-
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ers (P = 0.02, N = 6). Treatment with nephrotic (vs. control)
HDL reduced both binding (control nVLDL + control HDL,
0.64 ± 0.02; control + nephrotic, 0.43 ± 0.06; nephrotic + con-
trol, 0.69 ± 0.05; and nephrotic + nephrotic, 0.62 ± 0.04 mg
VLDL protein/mg cell protein) and lipolysis (control nVLDL +
control HDL, 0.053 ± 0.004; control + nephrotic, 0.038 ± 0.004;
nephrotic + control, 0.069 ± 0.004; and nephrotic + nephrotic,
0.062 ± 0.004 nmol NEFA/well/hour) (P < 0.05 vs. nVLDL +
control HDL) of nVLDL from either source. The apoE content
of nVLDL coincubated with control HDL or analbuminemic
HDL was increased compared nVLDL incubated with either no
HDL or nephrotic HDL (P < 0.05). Similarly, the apoE/apoA-I
ratio was reduced in HDL from nephrotic rats but not in HDL
from controls (P < 0.05). Reintroduction of apoE to nephrotic
VLDL resulted in increased binding.
Conclusion. Unlike circulating VLDL, binding of nVLDL
from isolated livers from nephrotic rats to endothelial cells
is greater and its lipolysis is increased compared to control
nVLDL. Decreased binding and lipolysis is conferred following
incubation with HDL isolated from control, but not nephrotic
rats and binding can be restored by reintroduction of apoE.
Thus both defects are conferred on VLDL by exposure to HDL
obtained from nephrotic animals, possibly a consequence of a
failure of nephrotic HDL to enrich VLDL with apoE during
clearance.
Hyperlipidemia is a common complication of the
nephrotic syndrome. While increased synthesis and de-
creased catabolism both contribute to hyperlipidemia, in-
creased very low-density lipoprotein (VLDL) levels are
largely the result of decreased clearance both in humans
[1] and rats [2]. Two separate defects contribute to re-
duced clearance. The first is a reduction in the lipoprotein
lipase (LpL) pool bound to the vascular endothelium [3].
LpL is largely responsible for lipolysis of triglyceride-rich
lipoproteins. LpL is produced by mesenchymal cells but
in its active form is tethered to apical heparan sulfate on
the vascular endothelium. Since only endothelial bound
LpL is available for interaction with circulating VLDL,
a reduction in this specific LpL pool results in reduced
lipolytic capacity.
The second defect is a binding defect intrinsic to the
VLDL. VLDL isolated from the plasma of nephrotic
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rats does not bind to vascular endothelial cells as ef-
fectively as does normal VLDL [4]. Since the binding
defect is not observed with VLDL isolated from analbu-
minemic rats, we postulated that reduced VLDL bind-
ing arose as a consequence of proteinuria rather than
of reduced serum albumin concentration or plasma on-
cotic pressure. The importance of the combined defect to
overall hyperlipidemia was illustrated by the observation
that despite a near absence of endothelial-bound LpL,
clearance of both VLDL and chylomicrons was nearly
normal and lipid levels were only slightly increased in
analbuminemic rats [3, 5]. Unlike the case of hereditary
analbuminemia the nephrotic rat has both the LpL de-
pletion and the VLDL binding defect. In these rats, clear-
ance of triglyceride-rich lipoproteins, chylomicrons, and
VLDL is greatly reduced and serum triglyceride concen-
trations are greatly increased. Thus, the binding charac-
teristics of VLDL from analbuminemic rats suggest that
it is possible to compensate for reduced lipolytic capac-
ity by increased VLDL binding and that reduced VLDL
clearance required a double defect.
It is not known how or when VLDL structure and func-
tion become abnormal in the nephrotic syndrome. VLDL
may be abnormal and have abnormal binding character-
istics at the time of secretion from the liver. Alternatively,
its structure and/or function may become abnormal fol-
lowing interaction with factors in the plasma.
We previously reported that functional changes on cir-
culating VLDL were induced by high-density lipopro-
tein (HDL). Both lipolysis and binding of circulating
VLDL were reduced by prior incubation with HDL from
nephrotic animals [4]. By contrast, VLDL exhibited im-
proved binding following incubation with control HDL.
The aim of the current study was to determine the struc-
tural and functional characteristics of nascent VLDL
(nVLDL) secreted by livers from nephrotic rats and to
determine whether HDL imparted an identifiable struc-
tural or functional defect on nVLDL.
METHODS
Animals
Sprague-Dawley rats were purchased from Simonsen
(Santa Clara, CA, USA). The nephrotic syndrome was in-
duced by intraperitoneal injection of FX1-A antiserum to
produce Heymann nephritis as described previously [6].
Analbuminemic rats were obtained from our own breed-
ing colony maintained at University of California Davis.
These animals were derived from animals obtained from
Jaap Joles (Utrecht, The Netherlands) and have been
bred as described previously [7]. All rats were kept in
24-hour light/dark rooms and fed ad libitum. The rats
were housed behind barriers in temperature regulated,
12-hour light-dark cycled rooms and were provided with
free access to standard rat chow until the evening be-
fore the experiments. Prior to all experiments, rats were
anesthetized with an intraperitoneal injection of 0.75 g/kg
(control) or 0.40 g/kg (nephrotic, analbuminemic) sodium
pentobarbital and exsanguinated by aortic puncture. All
protocols were approved by the Animal Resources Ser-
vice committees at University of California Davis and VA
Northern California Health Care System.
Chemical analysis
Enzymatic kits were used for the determination of
plasma triglyceride concentrations (Kit #339-10) (Sigma
Chemical Co., St. Louis, MO, USA).
Liver perfusion and generation of nVLDL
Livers were perfused based upon the method described
by Salam, Wilcox, and Heimberg [8]. Animals were anes-
thetized with sodium pentobarbital and placed on a heat-
ing pad at 37◦C. After 5 minutes, the abdomen was
opened, exposing the liver and gastrointestinal tract. The
tract was exteriorized to expose the hepatic portal vein
(HPV). Ligatures were placed loosely around the proxi-
mal and distal HPV and the posterior vena cava (PVC).
The HPV was cannulated, the PVC nicked, and per-
fusion immediately begun with 85 mL RPMI (Gibco,
Grand Island, NY, USA) + 1% bovine serum albumin
(BSA) (Sigma Chemical Co.) + 5 U/mL heparin at a flow
rate of 5 mL/min. The medium was equilibrated with
95% O2/5% CO2 at 100% humidity using gas perme-
able tubing and maintained at pH 7.4. Ligatures placed
around the hepatic artery were closed and a cannula
placed into the PVC via the right atrium. The flow rate
was increased to 15 mL/minute and the perfusate was
changed to a second solution containing 3% albumin
and no heparin. Finally, the perfusate was changed to
a third solution containing RPMI + 3% free fatty acid
(FFA)-free BSA (Sigma Chemical Co.), 25% washed
bovine red blood cells (Hemostat Labs, Dixon CA, USA),
and 0.91 nmol oleic acid (Sigma Chemical Co.). Dur-
ing the perfusion, a solution of oleic acid in 6% FFA-
free BSA was infused into the recirculation reservoir at
166 lmol/hour. This infusion rate was based upon the
study of Salam, Wilcox, and Heimberg [9] of oleic acid
infusion rates. Recirculation of 50 mL of the third solu-
tion began once erythrocytes were evident in the exiting
perfusate. In some cases, the perfusate contained either
1 mCi 3H-oleic acid (Amersham, Piscataway, NJ, USA) or
35S-methionine (Amersham). We measured the synthesis
of triglycerides and the incorporation of 35S-methionine
into trichloroacetic acid (TCA) precipitable proteins over
the course of a 2-hour perfusion and found that in the first
15 minutes of perfusion, total methionine counts in the
perfusate decreased to 70% of initial counts and then
remained unchanged for the duration of the perfusion
and was held at this level by the continuous addition of
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35S-methionine. The amount of 35S-methionine incorpo-
rated into proteins as measured by TCA precipitable
counts increased steadily to 33% of total counts per
minute by 120 minutes.
Isolation and content of lipoproteins
VLDL and HDL were used for several protocols.
Lipoproteins were isolated using the sequential flotation
method described by Schumaker and Puppione [10]. In
each case, plasma or liver perfusate was handled using the
method recommended by Edelstein and Scanu [11]. Af-
ter perfusion of livers, the nVLDL fraction still contained
large amounts of oleic acid as measured by presence of 3H
in FFA extractions. To remove excess FFA, nVLDL was
reisolated by layering nVLDL in a 6% FFA-free albumin
solution under a d = 1.006 solution, centrifuging and rec-
ollecting the VLDL fraction. This fraction contained no
3H in FFA extracts but did not lose any 3H triglyceride
activity.
Samples of VLDL before and after this flotation step
were scanned using a STORM imager (Molecular Dy-
namics, Piscataway, NY. USA) and stained with the
fluorescent marker SYPRO orange (Molecular Probes,
Eugene, OR, USA). This stain was selected because
its staining is uniform regardless of protein structure.
The images were analyzed using ImageQuant software
(Molecular Dynamics) based on the Scion images soft-
ware available from the National Institutes of Health.
VLDL was stored under nitrogen and used within 14 days
of collection.
Apolipoprotein content of VLDL was determined by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS PAGE) under denaturing conditions and subse-
quent STORM analysis. A standard curve using BSA was
generated for each gel. Incorporation of 35S-methionine
into each apolipoprotein was measured by exposure of
dried gels to a low-energy phoshorimaging plate (Molec-
ular Dynamics) and quantitation on a STORM imager.
Both apolipoprotein E (apoE) and apolipoprotein A-I
(apoA-I) content was similarly determined in HDL.
Incubation of VLDL with HDL
VLDL was incubated with HDL according to the
method of Furukawa et al [12]. A total of 350 mg VLDL
protein was incubated with HDL at a ratio of 0.7 mg
HDL protein to 1.0 mg VLDL tryglyceride. The solution
was then diluted with phosphate-buffered saline (PBS) +
0.05% sodium azide to 1.25 mL and incubated for 2 hours
at 37◦C. The VLDL was then reisolated.
To confirm the role of apoE, 50 lg of human recombi-
nant apoE (Calbiochem, La Jolla CA, USA) was coincu-
bated with 300 lg VLDL isolated from nephrotic rats. The
VLDL was then reisolated. This increased the apoE/apoB
ratio to 195% by SDS-PAGE. The binding was then as-
sessed.
VLDL binding
Binding of nVLDL to primary cultured bovine aortic
endothelial cells (BAEC) before and after co-incubation
with control or nephrotic HDL was measured as previ-
ously described [4]. Briefly, 10 lg/mL 3H-triolein-VLDL
protein was added to media containing RPMI, 25 mmol/L
Hepes, pH 7.4, 10% lipoprotein-deficient fetal bovine
serum (FBS), and 5 lg/mL LpL. Then, 300 lg/mL unla-
beled VLDL was used to determine nonspecific binding.
After 5 hours at 4◦C, the cells were rinsed and dissolved
in 0.25 mL 0.1 mol/L NaOH and counted on a Packard
gamma counter.
Lipolysis
Lipolysis was measured using a method developed by
de Man et al [13] from measuring lipolysis on a two-
dimensional surface. A total of 75 lL 1000 U/mL heparin
was incubated in 96-well Costar high binding plates for
18 hours at 4◦C. The wells were washed three times with
200 lL PBS. Nonspecific binding sites were blocked by
incubation of each well with 200 lL of 2 mg/mL albumin
at 37◦C for 1 hour. The wells were washed again three
times with 200 lL PBS. Next, 75 lL LpL at 5lg/mL in
10% glycerol + PBS at 4◦C was incubated in each well to
bind to the heparin sulfate. The wells were washed again
three times with 200 lL PBS at 4◦C and 75 lL 75 mg/
dL 3H-trioleate-labeled nVLDL either before or after
coincubation with HDL was added and the plate was in-
cubated at 37◦C. After 30 minutes, lipolysis was stopped
by cooling to 4◦C and immediate lipid extraction. A 65 lL
solution was removed from each well and transferred
to glass tubes. FFAs were extracted by the addition of
1.62 mL chloroform/MeOH/heptane (1.25:1.41:1.00) to
each tube. The tubes were vortexed and 0.50 mL of
0.4 mol/L boric acid/0.4 M K2CO3, pH 10.0, was added.
The samples were vortexed again for 15 seconds and then
centrifuged for 10 minutes at 1000g to separate phases.
One milliliter of the top phase was counted in liquid scin-
tillation fluid on a Beckman Scintillation counter. 0.1 mL
of the nVLDL was counted as standard for oleic acid
release.
Structure and function of nVLDL (experiment 1)
Livers from four control and four nephrotic rats were
perfused using 0.5 mCi 35S-methionine and four control
and four nephrotic livers were perfused with 1.0 mCi
3H-oleic acid and the resultant nVLDL isolated as de-
scribed above. 3H-VLDL was used to determine LpL-
mediated lipolysis and endothelial binding. 35S-VLDL
was used to measure VLDL apolipoprotein content and
35S-methionine incorporation.
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Structure and function of nVLDL after HDL
coincubation (experiment 2)
HDL from five control, five nephrotic, and five anal-
buminemic rats was isolated and pooled. The protein
content of each resulting HDL pool was coincubated
with nVLDL as described above. The lipoproteins were
isolated again following repeat ultracentrifugation. The
nVLDL was harvested from the top and HDL from the
bottom of the centrifuge tubes. 3H-VLDL were used to
determine lipolysis and binding and 35S-VLDL was used
to measure the apolipoprotein exchange. 35S-methionine-
labeled lipoproteins were used to establish the transfer of
specific apolipoprotein from one lipoprotein fraction to
another after coincubation.
The specific enrichment of each apolipoprotein in
nVLDL was known prior to incubation with HDL and
the concentration of each apolipoprotein was normalized
to total moles of apoB in the VLDL fractions. Follow-
ing reisolation, the change in specific enrichment of each
apolipoprotein was then used to calculate distribution be-
tween VLDL and HDL fractions. ApoA-I was used to
normalize the relative abundance of other apolipopro-
teins within the HDL fraction.
VLDL binding after direct addition of apoE
(experiment 3)
In order to demonstrate the direct effects of apoE,
VLDL from nephrotic rats was directly coincubated
with enough human recombinant apoE to increase the
apoE/apoB ratio to 195% of the original ratio. This frac-
tion was labeled with 1.0 mCi 125I using the method of Mc-
Farlane as modified by Helmkamp, Contreras, and Bale
[14]. The binding to BAEC was assessed in the same way
as described above.
Statistical analysis
Differences in binding were determined by two-way
analysis of variance (ANOVA) and linear regression and
nonlinear regression analysis were determined using ver-
sion 2.01 of Prism software. Differences of P < 0.05 were
considered significant.
RESULTS
Characteristics of nVLDL
nVLDL isolated from control and nephrotic rats
did not differ either in triglyceride or protein content
(control = 16.8 ± 1.8, nephrotic = 22.8 ± 3.7 mg
triglyceride/mg protein). The reduced apoE/apoB ratio
previously reported in circulating VLDL from rats [4]
or humans [15] was not present in nephrotic nVLDL
(Fig. 1A); however, significant amounts of apoA-I were
present. nVLDL from the livers of nephrotic rats was far
more enriched in apoA-I than was nVLDL obtained from
livers of control animals (Fig. 1A)
The absolute incorporation of 35S-methionine into all
exchangeable apolipoproteins was increased in nVLDL
obtained from nephrotic livers. Incorporation into apoA-
I was increased to 337% of control, incorporation into
apoE was increased to 142% of control and apoCs were
increased to 173% of control (Fig. 1B) relative to apoB.
Additionally, nVLDL from nephrotic livers contained
228% more apoA-I than did nVLDL isolated from livers
of control animals but the apoE content was not different
(Fig. 1C), supporting a model in which increased apoA-I
synthesis correlates with apoA-I content in nVLDL.
This was reflected in the greater specific activity (ra-
dioactivity/protein content) of apoA-I in nVLDL from
nephrotic rats compared to the specific radioactivity of
apoA-I from control nVLDL. While the specific radioac-
tivity of apoE in nVLDL derived from nephrotic livers
and control livers were similar, the specific radioactiv-
ity of apoA-I was greatly increased in nVLDL isolated
from nephrotic livers. To clarify the relationship between
apoA-I and apoE, we measured the relative content of
apoA-I and apoE in nVLDL. Whether measured by to-
tal protein or by 35S-methionine incorporation the rela-
tive content of apoA-I was greater in nephrotic nVLDL
(Fig. 1D). These differences are consistent with the
known magnitude of increase in the rate of apoA-I syn-
thesis in nephrotic rats [16, 17].
Binding and lipolysis
Binding of nephrotic nVLDL was 130% greater than
control levels (P < 0.05) (Fig. 2A). Similarly, lipoly-
sis of nVLDL from nephrotic livers was actually in-
creased significantly to 140% of control levels (P < 0.05)
(Fig. 2B). Thus, not only was there was no functional
deficit in nVLDL secreted by nephrotic livers, nVLDL
from nephrotic livers bound more avidly and was a bet-
ter substrate for lipolysis than was nVLDL isolated from
control livers.
Effect of HDL on nVLDL structure
Coincubation of nVLDL with HDL altered both struc-
tural and functional characteristics of all nVLDL. Expo-
sure to apoE-rich HDL from control or analbuminemic
rats increased the apoE content of nVLDL while expo-
sure to apoE poor nephrotic HDL did not (Fig. 3A). In the
case of control nVLDL, control HDL increased nVLDL
apoE content to 244% ± 12% of original (P < 0.05 vs.
control nVLDL + no HDL) but apoE content of con-
trol nVLDL was not increased significantly after incuba-
tion with nephrotic HDL. The effect of HDL source was
greater when the source of nVLDL was from nephrotic
livers. ApoE content of nephrotic nVLDL was increased
after co-incubation with control or analbuminemic HDL
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to 451% ± 51% and 390% ± 45%, respectively (P < 0.001
vs. nephrotic nVLDL + no HDL). By contrast there was
no change in apoE content of nephrotic nVLDL follow-
ing incubation with nephrotic HDL.
Coincubation with HDL decreased the specific ra-
dioactivity of apoE in all cases, indicating 35S-apoE on
nVLDL exchanged with apoE contributed by HDL. The
of apoA-I content. Nephrotic livers secreted a VLDL particle contain-
ing apoA-I, but the apoA-I content of VLDL from control livers was
low. (B) Rate of methionine incorporation across apolipoproteins. To
determine the relative content of new apolipoprotein and thus hepatic
contribution of apolipoprotein content to nVLDL structure, the amount
of radioactivity in each apolipoprotein normalized to apoB content was
determined and compared. (C) Apolipoprotein protein content. The
apoA-I and apoE content of nVLDL relative to apoB (D) ApoA-I
content of nVLDL. The amount of apoA-I relative to apoB is reported
as measured by either total protein or 35S-meth incorporation.
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decrease in specific radioactivity was less when nVLDL
was coincubated with nephrotic HDL, consistent with
a reduced apoE pool size in nephrotic HDL (Fig. 3B).
The relative size of the apoE pool was calculated from
the changes in specific radioactivity of apoE (Fig. 3C).
When incubated with control HDL, 35S-apoE from con-
trol nVLDL distributed into a pool 4.0 ± 0.4 times larger
than the original apoE pool. In contrast, when nephrotic
HDL was used, 35S-apoE from control nVLDL dis-
tributed into a pool only 1.4 ± 0.1 times larger (P < 0.5).
Thus, with control nVLDL, the control HDL provided
almost three times more exchangeable apoE than did
nephrotic HDL. When nephrotic nVLDL was the apoE
source, incubation with either apoE-rich HDL, control,
or analbuminemic, distributed apoE into a pool 12.0 ±
1.3 and 14.4 ± 1.2 times larger, respectively, than the
original nVLDL pool. When nephrotic nVLDL was in-
cubated with nephrotic HDL, the apoE from nephrotic
nVLDL distributed into a smaller pool that was only 2.9 ±
0.3 times larger. As in the case of control nVLDL, con-
trol HDL provided nephrotic nVLDL a larger exchange-
able apoE pool than nephrotic HDL did. However, in
the case of nephrotic nVLDL, control HDL provided 4.1
times more exchangeable apoE than did nephrotic apoE.
Despite any structural differences between control and
analbuminemic HDL, both provided similar amounts of
exchangeable apoE.
Effect of HDL on nVLDL function
Following incubation with nephrotic HDL, both bind-
ing and lipolysis of nVLDL was reduced compared to
nVLDL incubated with control HDL (Fig. 4). Bind-
ing of nephrotic nVLDL incubated with control HDL
was greater than binding of nephrotic nVLDL incu-
bated with nephrotic HDL (0.69 ± 0.05 vs. 0.62 ± 0.04
ng VLDL protein bound/mg cell protein) (P < 0.05).
Likewise, binding of control nVLDL was reduced fol-
lowing incubation with nephrotic HDL compared to
incubation with control HDL (0.64 ± 0.01 vs. 0.43 ±
0.06 ng VLDL protein bound/mg cell protein) (P < 0.05).
Regardless of the effects of HDL, binding of nephrotic
nVLDL was greater than binding of control nVLDL
(P < 0.05).
Incubation of nVLDL with HDL also affected lipolysis
of the resulting VLDL fraction (Fig. 4). When nephrotic
nVLDL was incubated with control HDL, lipolysis of
FFA from the resultant particle was greater than lipoly-
sis from the nephrotic nVLDL incubated with nephrotic
HDL 68.5±3.5 vs. 62±4.0 pmol FFA released/mg triglyc-
eride/hour) (P < 0.05). The effect of HDL on subsequent
lipolysis of control nVLDL was similar to what was ob-
served when the nVLDL was isolated from the livers of
nephrotic animals. Lipolysis of control nVLDL follow-
ing incubation with control HDL was greater compared
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Fig. 4. Effect of HDL on nVLDL function.
Basic functional characteristics of nascent
VLDL were assessed as described after
co-incubation with HDL from control or
nephrotic VLDL. 3H-nVLDL TG 1 mg was
co-incubated with 0.75 mg HDL protein from
either control, nephrotic, or analbuminemic
rats. (A) Binding of nVLDL after HDL co-
incubation. BAEC were incubated with 10
lg/mL 3H-VLDL in the presence of 5 lg/mL
LpL at 4◦C. After 5 hours, the cells were
washed and the remaining counts determined.
Non-specific binding was determined by ad-
dition of 300 lg/mL excess unlabeled VLDL.
(B) Nephrotic HDL impairs both nephrotic
and control nVLDL lipolysis. Release of
NEFA was measured after exposure of 96
well plates containing heparin bound LpL.
nVLDL TG 75 mg/dL was incubated at 37◦C
at pH 7.4 for 30 minutes. The accumulation of
3H-oleic acid was measured.
to that following incubation with nephrotic HDL (53.0 ±
3.5 vs. 37.5 ± 3.5). Quantitatively, the magnitude of the
effect that control HDL exerted on control nVLDL lipol-
ysis was greater than its effect on nephrotic nVLDL.
HDL structure after nVLDL coincubation
Two-way ANOVA revealed no interaction and the data
from control nVLDL and nephrotic nVLDL are shown
combined. After incubation with nVLDL, nephrotic
HDL contained 143.0 ± 5.0% (P < 0.05 vs. 100%,
P < 0.001 vs. control HDL) of the apoE they con-
tained prior to incubation while control HDL contained
93.6% ± 5.5% (NS vs. 100%) of their original apoE. Like
control HDL, analbuminemic HDL 93.1% ± 4.1% of
their original value (NS vs. 100%, NS vs. control, P < 0.01
vs. nephrotic) (Fig. 5). Thus, nephrotic HDL sustained
an increase in apoE/apoA-I ratio following incubation
with nVLDL while HDL from both analbuminemic and
control animals sustained a decrease in the apoE/apoA-I
ratio.
Effect of exogenous apoE on VLDL binding
After incubation with human recombinant apoE, the
apoE/apoB ratio was increased by 195%. Binding of
the resultant fraction was significantly increased from
0.207 ± 0.015 to 0.370 ± 0.027 lg VLDL protein bound/
mg cell protein (Fig. 6).
DISCUSSION
We have demonstrated that when VLDL is secreted
from nephrotic livers it both binds to endothelia and
serves at least as well as normal VLDL as a substrate
for LpL. It is only following interaction with HDL from
nephrotic animals that abnormalities in the binding or
lipolysis of VLDL are seen. Nephrotic HDL, but not
analbuminemic HDL, confers a defect onto otherwise
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Fig. 5. ApoE/apoA-I ratios in HDL after nVLDL co-incubation.
35S-nVLDL TG 1 mg was co-incubated with 0.75 mg HDL protein
from either control, nephrotic, or analbuminemic rats. HDL after co-
incubation was re-isolatd and run on 4–20% SDS-PAGE gels, stained
with SYPRO orange, and read on a STORM imager. The gel was then
dried and exposed to a phoshorimaging screen and the accumulated
radioactivity was measured with a STORM imager. To ensure equal
loading of the gels, each lane was normalized to total moles of apoA-
I. The data reported here represent the combined HDL exposed to
control and nephrotic nVLDL.
normally functioning nVLDL, contributing to delayed
clearance of mature VLDL from the circulation.
nVLDL is far more triglyceride rich than are circulat-
ing VLDL whether compared to VLDL obtained from
plasma of normal or nephrotic animals [4]; however,
there is no difference in the triglyceride/protein ratio
of nVLDL from either nephrotic or control livers. The
greater triglyceride content of nVLDL in comparison to
VLDL in the circulation suggests that VLDL isolated
from serum has undergone some degree of lipolysis and
catabolism and is not reflective of the structure of the
particle at the time of secretion. Furthermore, our find-
ings suggest that the greater triglyceride/protein ratio
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Fig. 6. Effect of exonous apoE on VLDL binding. Human recombinant
apoE 50 lg was co-incubated with 300 lg VLDL protein at 37◦C for
one hour then the VLDL was re-isolated. The VLDL was labeled with
125I and the binding to BAEC was assessed.
observed in VLDL isolated from serum is a consequence
of reduced lipolysis rather than the cause.
The rate of exchangeable apolipoprotein incorporation
relative to apoB was greater in nephrotic livers than in
control. Most markedly, both the content and the spe-
cific radioactivity of apoA-I were significantly greater in
comparison to control nVLDL. This is likely a result of
the increased apoA-I synthesis rate known to occur in
nephrotic rats [16]. Our findings suggest that transport of
a significant fraction of apoA-I from the liver of nephrotic
animals is within the structure of nVLDL. Since nVLDL
obtained from the livers of nephrotic rats was bound and
lipolyzed at least as well as nVLDL secreted from nor-
mal livers, it is unlikely that apoA-I, the major structural
moiety of HDL and a lecithin-cholesterol acyltransferase
(LCAT) activator, impairs catabolism of VLDL follow-
ing secretion. It is likely that apoA-I rapidly equilibrates
with HDL in vivo leading to a net transfer of essentially
all of the apoA-I to HDL.
Despite this difference, overall the composition of
nVLDL from control and nephrotic livers are quite sim-
ilar, in contrast to the differences found in circulating
VLDL from control or nephrotic animals. Nephrotic
VLDL in the circulation have increased triglyceride/
protein ratios, reduced apoE/apoB content and apoE/
total protein [4]. Similarly, circulating VLDL from
nephrotic humans have reduced apoC-II, apoC-III,
apoE, and triglyceride content per particle [15].
Since nVLDL secreted by either nephrotic or normal
livers are equally good substrates for lipolysis and en-
dothelial binding, the functional differences that occur in
circulating VLDL must occur following secretion. While
nVLDL from nephrotic livers is different than controls,
these changes in no way predict its metabolic fate once
VLDL enters the circulation and undergoes delipidation
and apolipoprotein exchange with HDL. Clearly, some
modification of the nascent particle takes place that re-
sults in the structurally and functionally deficient circu-
lating VLDL.
We previously reported that HDL from control animals
corrected the defect in binding of VLDL isolated from
nephrotic animals, while HDL isolated from nephrotic
animals imparted a defect in binding upon VLDL iso-
lated form normal animals [4]. Similarly, Furukawa et al
[12] showed that coincubation of circulating VLDL with
nephrotic HDL impaired lipolysis in vitro. We here doc-
ument that while control HDL are capable of donating
apoE, nephrotic HDL are not. When nVLDL are ex-
posed to control HDL, the apoE content is increased
while the specific radioactivity of the 35S-methionine-
apoE is reduced. The reduction in labeled apoE is a
consequence of apoE distributing across both nVLDL
and HDL into a larger apoE pool. The magnitude of
this reduction is a measure of the pool size into which
apoE distributes. While other investigators have reported
the presence of both exchangeable and nonexchangeable
pools of apoE present in lipoproteins [18, 19], the re-
duction in specific radioactivity of the 35S label specifi-
cally represents only the exchangeable apoE on HDL,
and thus characterizes the reduced ability of HDL from
nephrotic animals to deliver apoE to VLDL. By contrast,
when nVLDL is exposed to nephrotic HDL the apoE
content is unchanged and the specific radioactivity of the
35S-methionine-apoE is not reduced to the same extent
as following incubation with control HDL, and the apoE
pool size conferred by nephrotic HDL is much smaller
than the pool size contributed by control HDL.
After coincubation with nVLDL the apoE/apoA-I ra-
tio in nephrotic HDL was reduced suggesting nephrotic
HDL acts as an apoE sink rather than donating apoE to
nVLDL. While this remains a potentially important find-
ing, our measurements have not accounted for the addi-
tional accumulation of apoA-I from nVLDL and so the
data should be interpreted cautiously at this point. In this
light, the structural alterations measured in HDL after
incubation are consistent with the structural alterations
measured in nVLDL following incubation. After coincu-
bation with control HDL, nVLDL apoE content relative
to apoA-I was either equal to or decreased compared to
nVLDL not incubated with HDL. In contrast, nephrotic
HDL, incubated with nVLDL, actually have increased
apoE/apoA-I ratio, and transfer of apoA-I from nVLDL
to the HDL is more complete than transfer of apoE. We
conclude that nephrotic HDL, by failing to donate apoE
to VLDL, cannot mediate effective VLDL binding to the
vascular endothelium.
Analbuminemic rats have much of the same changes in
plasma protein composition as nephrotic animals. These
include increased levels of large plasma proteins such
as a2-macroglobulin fibrinogen, transferrin, and reduced
plasma oncotic pressure [20]. The other major difference
between analbuminemic and nephrotic rats is the obvi-
ous absence of urinary protein loss in the former and the
massive losses of plasma proteins into the urine in the
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nephrotic syndrome. Thus analbuminemic rats serve as a
control for the effects of hypoalbuminemia independent
of proteinuria. Like hypoalbuminemic nephrotic rats,
analbuminemic rats also have increased serum triglyc-
eride; however, the increase in triglyceride concentra-
tion is far less than observed in the nephrotic syndrome.
Like nephrotic rats, the levels of endothelial-bound LpL
are greatly reduced and decreased triglyceride clearance
is the cause of the small increase in triglyceride levels
observed [3, 5]. Despite the very low levels of LpL, the
clearance of chylomicrons in analbuminemic rats is nearly
normal and serum triglycerides are correspondingly only
slightly elevated [5]. Thus, analbuminemic rats manage in
some way to accommodate for the marked reduction in
endothelial-bound LpL.
In contrast to nephrotic HDL, analbuminemic HDL
had the same effect on nVLDL structure and function as
did control HDL. Like control HDL, HDL from analbu-
minemic rats enhanced VLDL binding and lipolysis. Fur-
thermore, analbuminemic HDL, while containing only
75% of the apoE as control, added the same amount of
apoE to nVLDL leading to a similar reduction in specific
radioactivity and identical pool sizes. The increased over-
all levels of HDL in analbuminemic rats [21] likely en-
hance this effect on apoE content in VLDL in vivo. Thus,
while the absolute amount of apoE in analbuminemic
HDL is reduced compared to control, the amount of ex-
changeable apoE in HDL from either source is the same.
Consequently, the ability of analbuminemic HDL to ex-
change apoE normally and facilitate binding of VLDL
remains intact unlike in nephrotic animals, suggesting
these properties of analbuminemic HDL allow it to over-
come the reduced lipolytic capacity presented by an
LpL-deficient endothelium. Consistent with this hypoth-
esis, infusion of apoE-rich control HDL improves triglyc-
eride clearance [4] in nephrotic rats.
While the reasons for the inability of HDL to effec-
tively donate apoE are unclear, Vaziri, Liang, and Parks
[22] have recently shown that LCAT activity is reduced
in the plasma of nephrotic rats. Reduced plasma activity
correlated with the appearance of LCAT activity in the
urine and there was no compensation for the urinary loss
of LCAT activity by hepatic synthesis. Furthermore, the
analbuminemic rat had no reduction of plasma LCAT
activity and normal urinary LCAT activity. These find-
ing strongly link LCAT deficiency to proteinuria rather
than hypoalbuminemia. LCAT is an important mediator
of the conversion of discoidal HDL into small spheri-
cal HDL and the eventual generation of larger spherical
HDL particles [23], and thus potentially contributing to
the exchange deficiencies of HDL.
The potential effect of apoE on hypertriglyceridemia
is opposite of the reported effects in some other mod-
els. Huang et al [24] have shown that overproduction of
apoE in the rabbit leads to hyperlipidemia and plasma
apoE levels correlate positively with serum triglyceride
and negatively with VLDL lipolysis [25]. This occurs
by increasing VLDL secretion and decreasing apoC-II
VLDL content. This occurs in part due to impairment of
VLDL lipolysis directly by apoE [26, 27], and is associ-
ated with decreased amounts of apoC-II in the VLDL
particle [28]. While apoE acts as a ligand for the bind-
ing of VLDL to endothelial cells, increased apoE/apoC
ratio normally induces hypertriglyceridemia rather than
ameliorates it. Nevertheless, there is clear evidence of the
importance of apoE in clearance of triglyceride-rich par-
ticles as the hypertriglyceridemic apoE knockout mouse
is resistant to post-heparin lipolysis [29] and LpL does not
promote the degradation of apoE deplete VLDL [30].
Furthermore, each of the models discussed is a model
in which LpL is readily available for lipolysis and clear-
ance of triglyceride from the particle. Since LpL is de-
pendent upon apoC-II as an activator, excessive levels
of apoE would displace apoC-II from the lipoprotein. In
the models of abundant lipase, a process that displaces
the LpL activator would have deleterious consequences
on overall triglyceride clearance. The nephrotic rat is a
model presenting an LpL-deplete endothelium. LpL is
the enzyme necessary for lipolysis of triglycerides, but it
also serves to bridge the binding of lipoproteins to the
endothelial surface by its interaction with heparan sul-
fate. Thus, LpL is an important in stimulating lipopro-
tein binding to the endothelial surface and to the VLDL
receptor. In both nephrotic or analbuminemic rats this
LpL-mediated binding is missing, and the model that re-
mains able to clear triglyceride is the one in which VLDL
binding remains normal. When LpL levels are reduced,
delivery to the endothelial surface may be more impor-
tant to triglyceride clearance than the availability of lipase
activators such as apoC-II.
As VLDL undergoes lipolysis on the normally LpL-
rich endothelial surface in normal animals, HDL contin-
ues to charge the partially catabolyzed VLDL particle
with apoE. Circulating VLDL must represent a partially
metabolized particle since its lipid content is so much
less than that observed in nascent lipoproteins. By con-
trast, no such contribution to VLDL occurs in nephrotic
plasma since HDL does not donate apoE to VLDL as
it undergoes its catabolic cycle. Since apoE is not avail-
able to VLDL from HDL, the circulating VLDL particle
is apoE deplete. This combined with the very low levels
of LpL on the vascular endothelium leads to the marked
increased levels of triglycerides in nephrotic animals.
The changes that we have established suggest that apoE
is transferred to nVLDL from HDL by control or HDL
obtained from analbuminemic rats, but not by HDL from
nephrotic animals. By contrast, apoE is not transferred
to nVLDL by HDL when it is obtained from nephrotic
animals. The different particle that results from interac-
tion with nephrotic HDL is responsible for the impaired
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function observed in circulating VLDL. We have exam-
ined the first step in what in vivo is an iterative process
and not a single catalytic event. The evidence for this it
the large excess of triglyceride found both in the nVLDL
and in nVLDL following initial incubation with HDL.
VLDL progressively loses triglycerides and ultimately is
released as a remnant particle that is then taken up by
the liver. VLDL isolated from the circulation represents
an intermediate form whose structure could be antici-
pated from the interaction that we have demonstrated to
occur in this first step of incubation with HDL. As this
process progresses, continued interaction with the abnor-
mal HDL circulating in the nephrotic syndrome should
lead to the progressive derangement in binding and lipol-
ysis that we have previously demonstrated in circulating
VLDL at the time of isolation from serum of nephrotic
animals or following incubation with HDL isolated from
serum of nephrotic animals.
These changes induced by nephrotic HDL impaired
nVLDL binding and lipolysis. In each case, the effect of
nephrotic HDL was to reduce binding and lipolysis. This
clearly establishes that HDL confers a defect on other-
wise normal nVLDL.
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